The mechanism for the inhibition of pyruvate dehydrogenase complex from bovine heart by moniliformin was investigated. Thiamin pyrophosphate proved to be necessary for the inhibitory action of moniliformin. The inhibition reaction was shown to be time-dependent and to follow first-order and saturation kinetics. Pyruvate protected the pyruvate dehydrogenase complex against moniliformin inactivation. Extensive dialysis of the moniliformin-inactivated complex only partially reversed inactivation. Moniliformin seems to act by inhibition of the pyruvate dehydrogenase component of the enzyme complex and not by acting on the dihydrolipoamide transacetylase or dehydrogenase components, as shown by monitoring the effect of moniliformin on each component individually. On the basis of these results, a suicide inactivator mechanism for moniliformin on pyruvate dehydrogenase is proposed.
INTRODUCTION
Moniliformin is a highly toxic fungal metabolite produced by several species of Fusarium, most of which are commonly found on basic foodstuffs (Rabie et al., 1982) . It is produced in large quantities (approx. 10 g/kg of growth medium) by some fungal isolates under laboratory conditions (Kriek et al., 1977) and has also been shown to occur naturally on maize . Moniliformin is normally isolated as the potassium or sodium salt of semi-squaric acid (1-hydroxycyclobutl-ene-3,4-dione) (Springer et al.. 1974) (Fig. 1) . It is acutely toxic to ducklings (LD50 = 3.68 mg/kg, orally), rats (LD50 = 50.0 and 41.6 mg/kg, orally, for males and females respectively) (Kriek et al., 1977) , cockerels (LD50 = 4 mg/kg, orally) (Cole et al., 1973) and mice (LD50 = 24 mg/kg, intraperitoneally) (Farb et al., 1976) . Ducklings and rats treated with moniliformin at the above-mentioned LD50 values undergo 'progressive muscular weakness, respiratory distress, cyanosis, coma and death' (Kriek et al., 1977) .
These clinical symptoms led Thiel (1978) to study the effect of moniliformin on energy yielding processes by measuring oxygen consumption after the addition of various substrates to isolated rat liver mitochondria. Micromolar concentrations of moniliformin were found to inhibit mitochondrial pyruvate and a-oxoglutarate oxidation selectively. The overall reaction of the a-oxo acid dehydrogenases can be represented as:
R-CO-COO-+ CoA + NAD+ -* R-CO-SCoA + CO2 + NADH + H+ where R = CH3 (pyruvate) or CH2-COO-(a-oxoglutarate) (Stanley & Perham, 1980) . The reaction is dependent on five cofactors, i.e. lipoate and FAD (both of which are bound to the complex), thiamin pyrophosphate, CoA and NAD+.
Pyruvate dehydrogenase complex from bovine heart consists ofpyruvate dehydrogenase (EC 1.2.4.1), dihydrolipoamide transacetylase (EC 2.3.1.12) and dihydrolipoamide dehydrogenase (EC 1.8.1.4) [for reviews see Reed (1974) and Hucho (1975) ].
Preliminary results of a study of the molecular mechanism of moniliformin inhibition led Hofmeyr et al. (1979) to propose that moniliformin acts as a suicide enzyme inactivator, which requires chemical activation by the target enzyme. A chemical reaction then occurs between the inhibitor and the enzyme, resulting in irreversible inhibition of the enzyme (Rando, 1974) . The present paper describes experiments designed to test the hypothesis that moniliformin acts as a suicide enzyme inactivator.
MATERIALS AND METHODS Reagents
All chemicals were of analytical reagent grade. Bio-Gel A-150m was purchased from Bio-Rad Laboratories, Richmond, CA, U.S.A. Moniliformin was isolated from pure cultures of F. moniliforme var. subglutinans grown on maize (Steyn et al., 1978) .
Enzyme isolation
The a-oxo acid dehydrogenase complexes were isolated from bovine heart by the procedure described by Stanley & Perham (1980) . This involved homogenization of the heart tissue, fractionation of the complexes with poly(ethylene glycol) and chromatographic purification of the partially purified complexes by gel filtration. The 
Inhibition of pyruvate dehydrogenase complex by moniliformin
Pyruvate dehydrogenase complex was incubated at 30°C with and without moniliformin for 60 min. In the absence of moniliformin, pyruvate dehydrogenase complex showed no loss of activity over 60 min. However, in the presence ofmoniliformin the inactivation of pyruvate dehydrogenase complex was time-dependent and followed first-order kinetics for at least 15 min (Fig.  2) . Subsequent experiments were done by determining the percentage inactivation after 5 min incubation. The inhibition reaction was shown to follow saturation kinetics (Fig. 3) .
These results were analysed by the theoretical model developed by Kitz & Wilson (1962) . In the equation k+i kinact E = free enzyme, I = free inhibitor, EI = enzyme-inactivator complex and EI = inactivated enzyme. Enzyme inactivation proceeds by a two-step mechanism in which equilibrium is maintained in the first step throughout the reaction. For each moniliformin concentration, the observed rate constant for inactivation (kobs) could be calculated from the half-time of inactivation (kObS = In 2/t.) obtained in Fig. 2 Varying the thiamin pyrophosphate concentration from 0 to 20 mm during incubation of pyruvate dehydrogenase complex with moniliformin indicated that the degree of moniliformin inhibition is dependent on the presence of thiamin pyrophosphate in the reaction mixture, but that the percentage inactivation decreases as the thiamin pyrophosphate concentration is increased from 0.5 to 20 mm (Fig. 5) .
Effect of pyruvate on moniliformin inhibition
Pyruvate dehydrogenase complex was treated with moniliformin in the presence of increasing concentrations of pyruvate. The inhibitory effect of moniliformin on pyruvate dehydrogenase complex was decreased with increasing concentrations of pyruvate (Fig. 6) , indicating a possible competition of moniliformin and pyruvate for the same site on the enzyme. Reversibility of moniliformin inhibition Pyruvate dehydrogenase complex was incubated both with and without moniliformin for 60 min at 30 'C. The activity of the complex was determined directly after incubation, after 6 h dialysis at 4 'C and again after a further 18 h dialysis at 4 'C ( Table 1 ). The uninhibited enzyme complex lost 15 % of its activity during dialysis. The inhibited enzyme complex, which lost 95% of its activity, regained only 10% of its original activity during dialysis, indicating a degree of irreversible binding of moniliformin to the complex.
Identification of the enzyme component(s) involved in moniliformin inhibition
The activities of the individual enzyme components of pyruvate dehydrogenase complex were determined in the presence and absence of moniliformin (Table 2) . Moniliformin had a negligible effect on dihydrolipoamide transacetylase and dihydrolipoamide dehydrogenase. However, pyruvate dehydrogenase activity was decreased by 82% in the presence of moniliformin.
DISCUSSION
Despite repeated attempts to improve the final yield and specific activity of the purified a-oxo acid dehydrogenase complexes, the specific activity of purified pyruvate dehydrogenase complex was only 50% of that reported by Stanley & Perham (1980) . The specific activity of purified a-oxoglutarate dehydrogenase complex was extremely low compared with reported values, which prevented an extensive study of the effect of moniliformin on this enzyme complex. The lower yield of the a-oxo acid dehydrogenase complexes could have resulted from an inherently lower content of these two enzyme complexes in the heart muscle used.
The inhibition of pyruvate dehydrogenase complex by moniliformin was dependent on the presence of thiamin pyrophosphate in the incubation mixture (Fig. 5) . The small amount of inhibition found when no thiamin pyrophosphate was added to the incubation mixture could be due to residual thiamin pyrophosphate bound to the enzyme complex. On the basis of structural similarity between moniliformin and pyruvate, as well as the dependence of inhibition on thiamin pyrophosphate, one can speculate that complex-formation between thiamin pyrophosphate and moniliformin on the active site of the enzyme is analogous to complex formation between thiamin pyrophosphate and pyruvate. At thiamin pyrophosphate concentrations above 2 mm, the excess of thiamin pyrophosphate could exchange with the moniliformin-bound thiamin pyrophosphate associated with the active site before moniliformin reacts with the enzyme and thereby decrease the inhibitory effect of moniliformin. Burka et al. (1982) have previously shown from spectroscopic and chromatographic data that a nonenzymic reaction between moniliformin and the primary amine group of thiamin hydrochloride does not take place. Rando (1975) pointed out that small-molecule toxins almost never function as simple isosteric competitive inhibitors of enzymes. These molecules often function by mechanisms which require them to be substrates for the target enzymes, leading to irreversible inhibition of the enzyme. There are a number of experimental criteria by which suicide enzyme inhibitors can be identified (Abeles & Maycock, 1976) :
(1) the loss of enzyme activity is time-dependent and first-order;
(2) the reaction follows saturation kinetics; (3) the rate of inactivation decreases as the substrate concentration is increased; (4) enzyme inactivation is irreversible because of covalent binding of the inhibitor to the enzyme.
The inhibition of pyruvate dehydrogenase complex by moniliformin is time-dependent and follows first-order kinetics (Fig. 2) . Time-dependence provides good, but not definitive, evidence that covalent modification has taken place. The inactivation of pyruvate dehydrogenase complex follows saturation kinetics. The rate of inactivation at a given moniliformin concentration decreases as the pyruvate concentration increases (Fig. 6) , indicating a protective effect by pyruvate against moniliformin inactivation. Substrate protection against inactivation confirms the involvement of the enzyme's active site in the inactivation process.
Determination of the activity of the individual component enzymes of the pyruvate dehydrogenase complex in the presence and absence of moniliformin indicated that moniliformin acts on pyruvate dehydrogenase and not on dihydrolipoamide dehydrogenase or dihydrolipoamide transacetylase.
Preliminary experiments indicated that radioactivity was irreversibly bound to the enzyme complex after inactivation with [14C]moniliformin and subsequent removal of unbound moniliformin by dialysis. However, the radioactivity was too low to be detected by autoradiography in the individual components of the complex after separation by SDS/polyacrylamide-gel electrophoresis. Final evidence for the covalent binding of moniliformin to pyruvate dehydrogenase complex would require the use of radioactively labelled moniliformin with a much higher specific radioactivity. It should then also be possible to show to which component enzyme the radioactivity becomes irreversibly associated. The use of labelled inhibitor will also allow the stoichiometry of labelling to be established.
